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INTRODUCTION 
 
 BP level per se has long been acknowledged as an unreliable 
indicator of subsequent morbid events in patients with primary 
hypertension. Recently, the concept that global cardiovascular risk, 
rather than the severity of hypertension, should guide both the 
decision to begin treatment and the identification of individual target 
pressure levels has been endorsed by international agencies 1, 2.  
 
In fact, results of large epidemiological studies clearly 
demonstrated that regardless of the severity of hypertension, the cost 
effectiveness of BP reduction by means of drug therapy is greater in 
the presence of target organ abnormalities and/or co-morbidities.  
 
In this context, assessment of subclinical organ damage, namely 
of left ventricular hypertrophy and peripheral atherosclerosis, 
however, very much depends on the diagnostic technique employed. 
Routine use of ultrasound technology, for example, leads to higher 
sensitivity in detecting cardiac and vascular structure abnormalities 
and allows identifying large number of high-risk patients. On the other 
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hand, the high prevalence of hypertension and its financial impact in 
health care systems should be carefully taken into consideration 
before recommending routine application of an expensive diagnostic 
approach to the stratification of risk.  
 
Thus, the development of low cost, accurate, clinical tools to 
identify hypertensive patients at highest risk is of the utmost 
importance. 
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OBJECTIVES OF THE STUDY 
 
 
1. To correlate the presence of microalbuminuria and the 
presence of subclinical target organ damage in patients with 
essential hypertension 
 
2. To ascertain relationship between amount of albumin 
excreted and severity of target organ damage. 
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REVIEW OF LITERATURE 
 
SYSTEMIC HYPERTENSION 
 
 An elevated arterial pressure is probably the most important 
public health problem in developed countries. It is common, 
asymptomatic, readily detectable, usually easily treatable, and often 
leads to lethal complications if left untreated.  
 
 The prevalence of hypertension depends on both the racial 
composition of the population studied and the criteria used to define 
the condition. In females, the prevalence is closely related to age, with 
a substantial increase occurring after an age of 50. This increase 
presumably related to the hormonal changes of menopause, although 
the mechanism is unclear. The ratio of hypertension frequency in 
women versus men increases from 0.6 to 0.7 at an age 30 to 1.1 to 1.2 
at age 65. Arterial pressure fluctuates in most persons whether they 
are hypertensive or normotensive. 
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Essential Hypertension 
 
 Patients with arterial hypertension and no definable cause are 
said to have Primary, Essential or Idiopathic hypertension. Many 
mechanisms involved in the regulation of the arterial pressure: 
peripheral; and/or central adrenergic, renal, hormonal, and vascular. 
These systems are integrated in a complex fashion with input from 
multiple genes. Several abnormalities have been described in patients 
with essential hypertension, often with claim that one or more of them 
are primarily responsible for the hypertension. 
 
 A number of environmental factors have been implicated in the 
development of hypertension, including salt intake, obesity, 
occupation, alcohol intake, family size, and overcrowding. These 
factors have all been assumed important in the increase in blood 
pressure with age in more affluent communities. 
 
 Salt intake has received the greatest attention as the 
environmental factor. This factor illustrates the heterogenous nature of 
essential hypertensive population. In brief, the pathophysiology is still 
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uncertain, but postulated contributing factors include chloride intake, 
calcium intake, a generalised cellular membrane defect, insulin 
resistance and “nonmodulation”. 
 
 Insulin resistance and/or hyperinsulinemia have been suggested 
as being responsible for the increased arterial pressure. This feature is 
now widely recognized as part of syndrome X or the metabolic 
syndrome.  
 
INSULIN RESISTANCE & HYPERTENSION 
 
 Insulin resistance is common in patients in patients with type 2 
diabetes mellitus and obesity; both of these conditions are more 
common in hypertensives than in normotensive subjects. However, 
several studies have found that hyperinsulinemia and insulin 
resistance are present even in lean hypertensives without type 2 
diabetes, suggesting that this relationship is more than a coincidence. 
  
Hyperinsulinemia can increase arterial pressure by one or more 
of the four mechanisms.  
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1) Hyperinsulinemia produces renal sodium retention (at least 
acutely) and increases sympathetic activity 
2) Vascular smooth muscle hypertrophy secondary to mitogenic 
actions of insulin. 
3) Insulin modifies cell membrane ion transport, thereby 
potentially increasing cytosolic calcium levels of insulin 
sensitive vascular or renal tissues 
4) Insulin resistance may be a marker for another pathologic 
process (nonmodulation). 
 
EFFECTS OF HYPERTENSION 
 
 Patients with hypertension die prematurely; the most common 
cause of death is heart disease, with stroke and renal failure frequent, 
particularly in patients with significant retinopathy. These 
complications are due to the target organ damage done by the 
increased arterial pressure. 
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Effects on heart 
  
 Cardiac compensation for the excessive workload imposed by 
increased systemic pressure is at first sustained by concentric 
hypertrophy and increased LV mass of left ventricle. Ultimately, the 
function of this chamber deteriorates, the cavity dilates, and the 
symptoms and signs of heart failure appear. Angina pectoris may also 
occur because of the combination of accelerated coronary arterial 
disease and increased myocardial mass. 
 
 Evidence of ischemia or infarction may be observed late in the 
disease. More deaths due to hypertension result from myocardial 
infarction or congestive heart failure. Recent data suggest that some of 
the myocardial damage may be mediated by aldosterone in the 
presence of a normal/ high salt intake rather than just the increased 
blood pressure or an increase in angiotensin II levels per se. Increased 
LV mass is one of the early indicators of subclinical target organ 
damage in patients with systemic hypertension. 
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NEUROLOGIC EFFECTS 
  
The neurologic effects of longstanding hypertension may be 
divided into retinal and central nervous system changes. Since retina 
is the only tissue in which the arteries and arterioles can be examined 
directly, repeated ophthalmoscopic examination provides the 
opportunity to observe the progress of the vascular effects of 
hypertension. The Keith-Wagener-Barker classification of the retinal 
changes in hypertension has provided a simple and excellent means 
for serial evaluation of hypertensive patients. 
Keith-Wagener-Barker classification 
Hypertensive retinopathy – Hypertension 
 
Degree 
General 
narrowing, 
AV ratio 
Focal 
Spasm Hge’s Exudates Papilledema 
Normal 3:4 1:1 - - - 
Grade I 1:2 1:1 - - - 
Grade II 1:3 2:3 - - - 
Grade III 1:4 1:3 + + - 
Grade IV Fine, fibrous 
cords 
Obliteration 
of distal 
flow 
+ + + 
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Arteriosclerosis 
 
Degree Arteriolar light reflex AV crossing defects 
Normal Fine yellow line, red blood 
column None 
Grade I Broadened yellow line, red blood column 
Mild depression of 
vein 
Grade II 
Broad yellow line “Copper 
Wire”, blood column not 
seen 
Depression or humping 
of vein 
Grade III 
Broad yellow line “Silver 
line”, blood column not 
seen 
Right angle deviation, 
tapering, 
disappearance of vein 
under the arteriole, 
distal dilatation of vein 
Grade IV Fibrous cords, blood 
column not visible Same as Grade III 
 
Central nervous dysfunction also occurs frequently in patients 
with hypertension. Occipital headaches, most often occurring in the 
morning, are among the most prominent early symptoms of 
hypertension. Light-headedness, tinnitus, vertigo, and dimness of 
vision or syncope may be observed, but the most serious 
manifestations are due to vascular occlusion, hemorrhage, or 
encephalopathy. The pathogeneses of the two former disorders are 
quite different.  
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Cerebral infarction is secondary to the increased atherosclerosis 
observed in hypertensive patients, whereas cerebral hemorrhage is the 
result of both the elevated arterial pressure and the development of 
cerebral vascular microaneurysms (Charcoat-Bouchard aneurysms). 
Only age and arterial pressure are known to influence the development 
of microaneurysms. Thus, it is not surprising that arterial pressure 
shows a better association with cerebral hemorrhage than with either 
cerebral or myocardial infarction.  
 
Hypertensive encephalopathy consists of the following symptom 
complex: severe hypertension, disordered consciousness, increased 
intracranial pressure, retinopathy with papilloedema, and seizures. 
The pathogenesis is uncertain but is probably related to arteriolar 
spasm or cerebral edema. Focal neurologic signs are infrequent and, if 
present, suggest that infarction, hemorrhage, or transient ischemic 
attacks are more likely diagnosis. Although some investigators have 
suggested that prompt lowering of arterial pressure in these patients 
may adversely affect cerebral blood flow, most studies indicated that 
this is not the case.  
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EFFECTS ON THE KIDNEY 
  
 Arteriosclerotic lesions of the afferent and efferent arterioles 
and the glomerular capillary tufts are the most common renal vascular 
lesions in hypertension and result in a decreased glomerular filtration 
rate and tubular dysfunction. Proteinuria and microscopic hematuria 
occur because of glomerular lesions, and about 10% of the deaths 
caused by hypertension result from renal failure. 
 
CLASSIFICATION OF HYPERTENSION 
 
 Systemic hypertension in any population is a continuous 
variable. Since there is no dividing line between normal and increased 
blood pressure, arbitrary levels have been established to define 
persons who have an increased risk of developing a morbid 
cardiovascular event and/or will benefit from medical therapy. These 
should be based on both systolic and diastolic pressure, age, sex, race 
and concomitant diseases.  
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 The level of systolic pressure is very important in assessing the 
influence of arterial hypertension on cardiovascular morbidity. Data 
increasingly suggest that it may be more important than diastolic 
pressure, especially in those over the age of 50. A reduction in 
mortality and morbidity with treatment of systolic hypertension, 
specifically in the elderly, has been documented. The beneficial effect 
results from a reduction in strokes mainly.   
 
European Society of Hypertension – European society of Cardiology 
guidelines for arterial hypertension – Classification2 
 
1) Based on the average of 2 or more readings taken at each of 
two or more visits after an initial screening 
2) Adults aged 18 years or more 
3) Patient should not be taking antihypertensive drugs or in a 
acutely ill state 
4) Higher category should be selected when systolic and 
diastolic BP fall in two different categories  
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Category Systolic BP, mmHg Diastolic BP, mmHg 
Optimal <120 <80 
Normal <130 <85 
High Normal 130-139 85-89 
Hypertension   
     Stage 1 (Mild) 140-159 90-99 
     Stage 2 (Moderate) 160-179 100-179 
     Stage 3 (Severe) ≥180 ≥110 
     Isolated Systolic HTN ≥140 <90 
 
 
Joint National Committee – Seventh report (JNC 7 Classification)1 
2003  
 
BP classification SBP in mmHg DBP in mmHg 
Normal < 120 and < 80 
Prehypertension 120-139 or 80-89 
Stage 1 hypertension 140-159 or 90-99 
Stage 2 hypertension ≥ 160 ≥ 100 
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Investigations 
 
 The basic tests to be performed in all patients are described 
below 
1. Always included 
a. Urine for protein, blood, and glucose 
b. Microscopic analysis 
c. Hematocrit 
d. Serum potassium 
e. Serum creatinine and/or blood urea nitrogen 
f. Fasting glucose 
g. Total cholesterol 
h. Electrocardiogram 
2. Usually included, depending upon cost and other factors 
a. Thyroid stimulating hormone 
b. White blood cell count 
c. HDL, LDL, and Triglycerides 
d. Serum calcium and phosphate 
e. Chest X-ray 
f. Limited Echocardiogram 
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Special studies to screen for secondary hypertension: 
 
1. Renovascular disease: ACE inhibitor radionucleotide renal scan, 
Renal duplex Doppler studies, and MRI angiography 
2. Pheochromocytoma: 24-h urine assay for creatinine, 
metanephrines, and catecholamines 
3. Cushing’s syndrome: Overnight dexamethasone suppression test 
or 24-h urine cortisol test 
4.  Primary aldosteronism: Plasma aldosterone: renin activity ratio 
 
 
MICROALBUMINURIA 
 
 Microalbuminuria (MAL) is defined as abnormally elevated 
excretion or concentration of albumin in urine but without clinical 
proteinuria. The term MAL was coined by Guy’s Hospital group in 
London (Liberty et al)3 1982. 
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Studies as early as 1982 by Viberti et al. showed increased 
albumin excretion even with normal proteinuria may herald onset of 
nephropathy4. 
 
 Microalbuminuria is found in 8 to 15% of hypertensive patients 
and cannot be detected by routine urine tests 5-8. However, several 
sensitive, reliable techniques (radioimmunoassay, enzyme linked 
immunosorbent assay, nephelometry)  have  now become widely 
available in clinical practice 9.  
 
The relatively large variability of microalbuminuria reported in 
nondiabetic hypertensive patients is likely due to differences in the 
techniques used to detect it and in the criteria used for patient’s 
selection. Thus, lower values have been reported in patients taking 
antihypertensive drugs, especially those that interfere with the renin-
angiotensin system (RAS), or in those with a milder degree of 
hypertension. In addition, the modality of urine collection (spot versus 
24 hrs) and the number of samples collected for each patient 
significantly contribute to the observed differences. 
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Screening for MAL in urine can be performed in three ways10 
 
1) Measurement of albumin creatinine ratio in random collection 
2) 24 hours collection 
3) Timed collection 
 
Definitions of abnormality in albumin excretion 
 
Category 
24hrs 
collection 
mg / 24 hrs. 
Timed 
collection 
µg / min 
Spot 
collection 
µg/mg of 
creatinine 
Normal <30 <20 <30 
Microalbuminuria 30 – 300 20 – 200 30 – 300 
Clinical albuminuria >300 >200 >300 
  
 
MAL: Normal variants 
 
 The urinary albumin excretion rate can vary highly from day to 
day up to 40%. Early morning urine specimens have been reported to 
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have smaller variations. Measurement of 24 hr. urine volume has 
probably the lowest variability. Hence, more than one urine collection 
has been advocated as necessary before convincingly labeling a 
patient microalbuminuric. 
  
 Transient increase in albumin excretion occurs in acute illness, 
stressful situations, exercise, water diuresis, prolonged upright 
posture, poor metabolic control in diabetics. 
 
 Higher urine albumin excretion was also noted in people of 
Asian origin, people with high BMI, daytime urine samples and with 
increasing age. 
 
 MAL can be found in diabetics and non-diabetic individuals 
with hypertension, UTI, cardiac decomposition and non-diabetic renal 
disease. 
 
Ratio of urinary albumin to creatinine ratio in a random sample 
of urine has become a widely accepted tool for assessing UAE in 
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clinical practice11 The AC ratio seems to be as effective as 
measurement of UAE by other methods.  
 
Methods of measurement of human albumin in urine 
 
 Several methods were employed with varying sensitivity, 
measurement time for urine albumin excretion. They were as follows: 
 
  Method      Time for assay 
 
Single radial immunodiffusion Mancini et al  1 day 
Electroimmunossay12   Laurell 1966  4-6 hrs 
Immunoturbidometric assay13 Teppo 1982  20-30 min 
RIA14     Keen 1963   1-2 days 
ELISA15     Fielding 1983  5-6 hrs 
Zone immunoelectrophoresis  Vesterberg   16-18 hrs 
Fluorescent immunoassay15  Charves 1984  4-6 hrs 
Immuno nephalometry16  Vasquez 1984  6 hrs 
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Micral test17 
  It is a semiquantitative test for estimation of urine 
albumin, which has to be confirmed further, by quantitative tests. In 
this test, urine albumin combines with soluble antialbumin 
galactosidase conjugate, which moves on substrate pad where 
galactosidase reacts with chlorophenon red galactoside changing color 
from yellow to red. 
  
Microalbuminuria: Physiological considerations 
 
 The glomerular transport of albumin depends upon several 
factors, the electric charge and size of the molecule, membrane status 
and specific renal hemodynamics18. The fractional excretion of 
albumin which is defined as fraction of albumin clearance rate is low 
(<0.1%) due to negative charge and large molecular size of albumin. 
 
Onset of microalbuminuria and its determinants 
 
 The stage of transition between normoalbuminuria and 
microalbuminuria has attracted much interest. The exact mechanism  
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behind the defect in filtration barrier is not yet known. Studies in 
patients with MAL have show conflicting results regarding 
pathophysiological changes in the glomerular and extraglomerular 
compartment. The structural and functional abnormalities in diabetic 
kidney results due to interplay between varieties of genetic, metabolic, 
haemodynamic alterations. 
 
Mechanisms of Nondiabetic Microalbuminuria 
 
 The pathogenic mechanism(s) underlying the development of 
microalbuminuria are currently poorly known. The severity of BP load 
and the increased systemic permeability to albumin, possibly due to 
early endothelial dysfunction, seem to play a major role, although 
several data suggest interplay with a number of additional factors, 
such as lipid abnormalities, prothrombotic factors, increased activity 
of RAS, and systemic inflammation. Finally, a functional 
haemodynamic abnormality and/ or the presence of structural changes 
within the kidney cannot be ruled out as causes of microalbuminuria.  
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Irrespective of its exact nature and pathogenesis, the 
unfavorable prognostic significance of albuminuria has recently been 
confirmed by long-term longitudinal studies19,20. Based on these data, 
an increased urinary albumin excretion (UAE) can be regarded as a 
specific, cost-effective tool for the identification of patients at highest 
risk and searching for microalbuminuria can be recommended as part 
of the initial work-up of every hypertensive patient. Screening for 
microalbuminuria should be included in initial investigations in the 
management of systemic hypertension and also in type 2 diabetes 
mellitus. 
 
Pathogenesis of microalbuminuria in hypertension 
 
Many patients with high blood pressure have a renal abnormality. 
However, the exact relationship between increased glomerular pressure that 
may be derived from increases in systemic blood pressure, or the specific 
increases in local intraglomerular pressure without similar changes in 
systemic pressure and glomerular malfunction have yet to be determined. 
Although the underlying mechanism responsible for albuminuria in 
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hypertension remains speculative, recent studies suggest that factors other 
than changes in glomerular permeability should be considered.  
 
These studies have demonstrated that albumin excretion in healthy 
controls is associated with comprehensive degradation (>95%) by lysosomes 
in renal cells distal to the glomerular basement membrane (GBM)57. 
Previously it was assumed that virtually all proteins filtered by the kidney 
were excreted intact. In fact <5% of albumin is excreted intact and 
detectable by conventional immunochemical assays. The remaining >95% is 
degraded and undetectable by routine immunochemical assays.  
 
The lysosomal processing of filtered albumin before its excretion has 
been shown to be an extremely rapid and efficient process. It occurs within 
minutes and involves lysosomal uptake and exocytosis of peptide products 
back to the tubular lumen by renal cells distal to the GBM.57-62. There is 
negligible contribution of albumin fragments arising from proteolytic 
activity on the luminal surface of the tubular cells63, from extra renal 
sources,57 or from contraluminal uptake of albumin with subsequent 
degradation.63  
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Similar rapid lysosomal processing has been demonstrated in vivo 
associated with the filtration and excretion of dextran sulfate in which the 
dextran sulfate is completely desulfated but not depolymerized. The ratio of 
intact to degraded forms of albumin and dextran sulfate has been shown 
previously to increase in experimental diabetic nephropathy. The increased 
ratio of intact to degraded albumin has also been shown in type 1 diabetic 
patients with diabetic nephropathy.58 
 
Furthermore, aminoguanidine (an antiglycation agent) and ramipril 
(an ACE inhibitor) have been demonstrated to normalize the protein 
fragmentation/desulfation process in rats with streptozotocin - induced 
diabetic nephropathy.  
 
These results may be linked to changes in transforming growth factor-
β (TGF-β) expression, which is upregulated in diabetes and other kidney 
disease states and may be upregulated in hypertension as a result of 
increased stretching forces brought about by the hypertensive state. Recent 
studies have shown that lysosomal activity may be affected by increased 
TGF- β levels, and its role in albuminuria induction may be further 
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supported by the fact that ACE inhibitors and decreasing albuminuria are 
correlated with decreased TGF- β levels.  
 
Microalbuminuria and high cardiovascular risk 
 
 An increased UAE has been associated with a number of 
unfavorable metabolic and nonmetabolic risk factors, such as older 
age, longer duration of hypertension, cigarette smoking, increased BP 
load and variability (the so-called non-dipping phenomenon), higher 
uric acid levels, worse lipid profile, insulin resistance, endothelial 
dysfunction, increased activity of the RAS, and BP salt sensitivity21.  
  
 Furthermore, microalbuminuria is a concomitant of subclinical 
organ damage in nondiabetic hypertensive patients6,22. Tuttle et al23 
showed a correlation between increased UAE and severity of coronary 
artery disease by coronary angiography. In another study Berton et 
al24 showed that the presence of microalbuminuria strongly predicts 
mortality in patients with acute myocardial infarction, even after 
adjusting for several other confounding factors, such as age, the 
presence of hypertension, heart failure, and serum lipids. Increased 
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UAE has also been related to peripheral atherosclerosis and increased 
carotid intima-media thickness (IMT) in some but not in all 
studies22,25.  
 
 In light of the well-known association between carotid 
atherosclerosis and cerebrovascular damage (both asymptomatic 
vascular lesions and acute events), it is not unexpected that 
microalbuminuria has been shown to be a predictor of ischemic stroke, 
even after correcting for the presence of several confounding factors26.  
 
 Several retrospective and prospective studies27-30 have 
demonstrated that microalbuminuria predicts cardiovascular morbidity 
and mortality in addition to being the earliest manifestation of 
nephropathy. Thus finding of MAL in diabetic patient is an indication 
for screening for possible cardiovascular disease and aggressive 
intervention to reduce all cardiovascular risk factors31 
 
 The mechanisms that link MAL and death from cardiovascular 
disease are poorly understood. Adverse changes in several 
cardiovascular risk factors have been found in microalbuminuric  
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diabetic subjects including hypertension, raised triglycerides, LP (a), 
fibrinogen, PAI-1. However, even most unfavorable combination of 
these factors would seem unlikely to explain the excess cardiovascular 
risk.  
 
 Moreover, studies by Haffner et al.32 have shown that 
nondiabetic subjects with microalbuminuria have higher prevalence of 
cardiovascular disease and increased mortality. All these suggest 
microalbuminuria is an independent risk factor for the development of 
cardiovascular disease. 
 
MAL and Cardiovascular risk in general population 
 
 Yudkin et al in 1988 were first to report that even in nondiabetic 
subjects, UAE significantly correlated with prevalence of 
atherosclerotic heart disease33. Damsgard et al34 also reported 
decreased survival rate in microalbuminuric non-diabetic when 
compared with normoalbuminuric subjects. 
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 In a large population study from New Zealand, the parameters 
that correlated positively with UAE were BMI35, smoking, blood 
pressure36, ethnicity37. However, the strongest risk factor for 
developing MAL was in fact the existence of hyperglycemia. 
 
 A recent Finnish study in 1069 non-diabetic subjects also found 
that high UAE values correlated with coronary mortality and 
morbidity and coexistence of MAL and hyperinsulinemia was even 
stronger cardiovascular risk factor38. 
 
 The evidence therefore suggests that even normotensive non 
diabetic microalbuminuric subjects have more atherogenic profile and 
tend to be more insulin resistant than normoalbuminuric subjects. 
Measurement of UAE in general population can thus be helpful in 
evaluation of cardiovascular risk39. 
 
Microalbuminuria and renal damage 
 
 Hypertension has recently been reconsidered (reevaluated) as a 
cause of chronic kidney disease. Evidences from large prospective 
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studies suggest that even mild increases in BP entail, in the long term, 
a strong independent risk of developing end-stage renal disease40. 
While benign nephrosclerosis occurs less frequently than other 
hypertensive complications (such as myocardial infarction and stroke), 
the large number of patients with high BP, together with the high 
social and financial costs of renal replacement therapy, make the 
prevention of this complication a relevant public health problem.  
 
  In fact, hypertension together with diabetes is currently a 
leading cause of end-stage renal disease in developed countries and 
most of the developing countries esp. in India. In the quest for new 
clinical tools that enable the identification of patients at highest renal 
risk, microalbuminuria has emerged as a strong candidate. 
 
  It has been proposed that this subclinical condition may signal 
the presence of functional and/or structural renal abnormalities that 
precede and predict the onset of GFR deterioration. In a relatively 
small retrospective study, microalbuminuria predicted subsequent loss 
of renal function, despite similar baseline clinical characteristics and 
current BP levels through the study period41.  
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Interestingly, increased renal vascular resistance, a parameter that has 
previously been shown to correlate with the severity of renal 
impairment in patients with chronic kidney disease, has been reported 
in patients with long-standing primary hypertension and 
microalbuminuria42,43. More recently, provocative data from a large 
cross-sectional study indicate that high normal albuminuria 
(somewhere between 15 to 30 mg/dL) is associated with 
hyperfiltration and similarly to diabetes mellitus, it could anticipate a 
decline in renal function44.  
 
 In conclusion, although large, well-conducted prospective 
studies addressing this issue are yet to be carried out, the predictive 
value of microalbuminuria for hypertension-induced renal damage is 
at present a tempting but speculative hypothesis. 
 
Tubular changes in microalbuminuria  
 
 Increased sodium, glucose reabsorbtion from proximal tubule 
has been reported in microalbuminuria patients. This can diminish 
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distal sodium delivery thereby stimulating tubuloglomerular feedback 
mediated enhanced of GFR. 
 
Microalbuminuria and endothelial dysfunction 
 
 MAL has been reported as a marker of generalized endothelial 
damage. This is the basis for ‘Stenohypothesis’45 which states that 
transmembrane passage of albumin is facilitated when production of 
heparan sulphate is reduced with consequent loss of negative charge. 
Poor glycemic control inhibits the enzyme N-deacytylase responsible 
for heparan sulphate production. 
 
 The endothelial dysfunction associated with MAL is not 
confined to renal glomerulus, but also involving other organs. This is 
evident from increased prevalence of MAL in hypertensives46 and 
patients with diabetic retinopathy. 
 
 Patients with MAL have increased levels of VWF, activated 
factor VII (VIIa), thrombomodulin that are all markers of endothelial  
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dysfunction when compared to normoalbuminuric47 group invoking 
probable generalized endothelial dysfunction in these patients. 
 
Smoking appears to be an important link between MAL and 
endothelial damage or dysfunction in diabetics48. Increased VWF is an 
index of endothelial injury has been demonstrated in smokers. 
 
MAL and insulin resistance 
 
 Insulin resistance has been associated with increased sodium 
reabsorbtion. This suggests that hyperinsulinemia may be one of the 
causal factors for development of MAL. 
 
 In a study of 333 treated hypertensives UAE was found to 
correlate with fasting insulin and sum of insulin at times 0, 30, 60, 90, 
120 minutes during an oral glucose tolerance test49. In another study 
of 25 hypertensives and 20 controls, undergoing OGTT, 
microalbuminuric hypertensives had higher insulin area under curve 
values when compared to 15 normoalbuminuric hypertensives50. 
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 The precise pathophysiological link between MAL, 
hyperinsulinemia is obscure. It is possible that either these phenomena 
are genetically determined and cosegregate in the same patient or 
hyperinsulinemia may cause both microalbuminuria and hypertension 
probably by altering membrane permeability51. 
  
Interventions to reduce MAL 
 
1) Glycemic control 
 
  The first step to prevent further renal damage after onset of 
MAL is control of hyperglycemia, which has been shown conclusively 
to slow the progression. 
 
2) Antihypertensive therapy52 
 
Mogensen et al53 emphasized and demonstrated that reduction of 
BP slows the progression of diabetic nephropathy. It appears that ACE 
inhibitors and Angiotensin Receptor blockers offer maximum benefit. 
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Several reports support an antiproteinuric effect of ACE inhibitors 
beyond their effect on BP.  
 
ACE inhibitors preferentially dilate the efferent arterioles 
resulting in reduction of intraglomerular pressure, decrease in 
macromolecular traffic through mesangium, increased bradykinin in 
renal circulation, and potassium sparing effect, which is 
vasoprotective at the level of endothelium54. It has growth inhibiting 
properties over mesangial cells and extra cellular matrix also. Studies 
have proven beyond doubt antiproteinuric effects of ACEI, which 
should be started even in normotensive diabetic subjects to retard the 
progression of diabetic nephropathy. 
 
3) Low protein diet 
 
 This reduces degree of decline in GFR and proteinuria. The 
mechanism involves decrease in glomerular hyperfiltration by relief 
from two effects of nitrogenous waste products namely afferent 
arteriolar dilatation and increased osmotic activity. 
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4) Others 
 There are ongoing intensive studies to find out treatment 
strategies to decrease albumin excretion. In one such study aldose 
reductase inhibitors found to reduce GFR and AER in type 1 diabetes. 
However, in type 2 diabetes these effects remain to be proven. 
 
MAL: THE FUTURE 
 
 Changes in albumin excretion and MAL in hypertension is likely 
to be more than an epiphenomenon. Data suggest what it is of value as 
an index of vascular damage. With increasing information available on 
its association with traditional cardiovascular risk factors, MAL may 
be a simple, cheap, easy measure of endothelial damage and further 
cardiovascular risk in hypertension. 
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MATERIALS AND METHODS 
 
250 patients, newly diagnosed or recently diagnosed (less 
than one year, on treatment), essential hypertensives following 
up at the hypertensive clinic, Government General Hospital, 
Chennai were enrolled for the study between May 2004 and June 
2005. Of them, 192 patients were excluded as per exclusion 
criteria. Remaining 58 patients were selected for the study who 
satisfied all the exclusion and the inclusion criteria. Written 
consent was obtained from all patients participated in the study. 
 
Exclusion criteria:  
 
1. Patients older than 60 years 
2. Hypertension duration > 1 year 
3. Diabetes mellitus, chronic kidney disease 
4. Chronic heart failure 
5. Positive history (or) clinical evidence of IHD 
6. Patients on diuretics, ACEIs, ARBs  
7. Severe obesity 
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Diagnosis of essential hypertension was made after complete 
medical history, physical examination and routine biochemical 
evaluation. Hypertension was defined according to the criteria in the 
European society of Hypertension – European society of Cardiology 
2003 guidelines for hypertension as an average blood pressure ≥ 
140/90 mmHg an at least two different occasions or by the presence of 
antihypertensive treatment.  
 
 On the study day, after an overnight fast, height and 
weight measured and venous blood was drawn in order to measure 
hematological parameters. Blood pressure was measured with patient 
in the sitting position after a 5 min rest, with mercury 
sphygmomanometer (cuff size 12.5 x 40 cm). The SBP and DBP were 
read to the nearest 2 mmHg. Disappearance of Korotkoff’s sounds 
(phase V) was the criterion for DBP. Body mass index (BMI) was 
calculated by the formula 
 
BMI = Weight (kg) / Height (m) 2 
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Standard 12 lead ECG was obtained for each patient. Serum 
creatinine, Blood urea, Serum electrolytes, Serum uric acid, Total 
cholesterol, Triglycerides, High-density lipoprotein – cholesterol 
(HDL-C) and other standard blood chemistry evaluations were 
performed according to routine methods. Low density lipoprotein 
(LDL) – cholesterol was calculated using Friedewald’ formula 
 
 LDL = TC – HDL-c – TGL/5 (IF TGL < 400 mg/dL) 
 
Creatinine clearance was calculated using Cockcroft – Gault’s 
formula and expressed in ml/min. These patients were subsequently 
investigated at Department of Cardiology, Barnard Institute of 
Radiology, Govt. General Hospital and biochemical investigations 
were carried out at biochemical lab attached to Institute of 
Biochemistry, Govt. General Hospital.  
 
STUDY DESIGN 
To evaluate the presence of microalbuminuria as an indicator of 
target organ damage in patients with essential hypertension, a single 
centre matched case-control study design was chosen. 
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Laboratory methods 
 
 Measurement of urine albumin excretion was done by collecting 
24-hour urine samples from our patients. The method was based on 
the measurement of immunoprecipitation of albumin enhanced by 
polyethylene glycol at 340 nm. The specific antiserum was added in 
excess to buffered samples.  
  
 The increased in absorbance caused by immunoprecipitation was 
recorded when the reaction reached its end point. Absorbance is 
proportional to amount of antigen in solution. The patients were 
divided into cases and controls by measurement of urine albumin (30-
300 case, <30 control) respectively. 
 
Echocardiography 
 
 All echocardiographic studies were performed in our 
Department of Cardiology using ALOKA machine. Echocardiograms 
were obtained at rest with patient’s supine in the left lateral position, 
using standard parasternal and apical views. The overall 
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monodimensional left ventricular measurements and the bidirectional 
(apical four and two chamber views) obtained according to the 
recommendations of the American society of Echocardiography55.  
 
 All electrocardiograms were done by a single observer blinded 
to the clinical characteristics of the patients under observation. LV 
mass index derived using the formula described by Devereux and 
associates: 
 
   LV mass (grams) =  
0.80 x 1.04 [(VSTd+LVIDd+PWTd)3-(LVIDd)3] + 0.6     
  where 
 VSTd – Ventricular septal thickness in diastole 
 LVIDd – LV internal dimension at end diastole 
 PWTd – LV posterior wall thickness at end diastole 
LV mass corrected for height and expressed in units of 
grams/m2.7 
The presence of LV hypertrophy was defined for LVMI > 51 gm/m2.7 
in either gender 
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Common carotid US scan 
 
 The intima-media thickness (IMT) of both carotid arteries was 
evaluated by high resolution US scan as described by Weldelhag56. 
Carotid arteries were investigated in the longitudinal and the 
transverse projections by high-resolution real-time ultrasonography 
using a 10 MHz in-line duplex system. The carotid artery was scanned 
at the bifurcation and at the common carotid artery.  
 
 At each longitudinal projection the far-wall IMT, as defined by 
Weldelhag et al.56, was measured at the distal end of CCA, 10 mm 
caudally to the point where the near and far walls lose their parallel 
configuration. Carotid plaque was defined as IMT > 1.3 mm. IMT was 
always measured on the CCA outside the plaque, if was present. Each 
value was calculated by taking averages of three readings.  
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STATISTICAL ANALYSIS 
 
 Statistical analysis was carried out for 58 subjects 32 persons in 
the control group whose albumin excretion is within normal limits, 26 
persons in the microalbuminuric group after categorizing each 
variable. Patients age, sex, weight, BMI, Serum lipid profile were 
matched.  
  
 Occurrence of target organ damage by IMT, LV mass index and 
Fundal examination were tabulated and analyzed. Microsoft excel 
2003 was used for analysis and Z tests were done to assess differences 
between percentages and difference between means. Correlation was 
evaluated by the software. Statistical significance was taken when 
P<0.05. 
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OBSERVATIONS 
 
Table No. 1 
Matching of cases and controls 
 
 
Microalbuminuric 
group 
Mean ± SD 
Normoalbuminuric 
group 
Mean ± SD 
‘P’ value 
Number 26 32  
Age 46.27 ± 7.96 45.16  ± 8.42 0.93 
Men / Women 14 / 11 18 / 14  
BMI 27.33  ± 3.51 25.99 ± 3.83 0.16 
Mean duration 4.31 ± 2.83 3.88 ± 2.50 0.54 
Systolic BP 146.08 ± 21.70 139.19 ± 8.84 0.13 
Diastolic BP 93.15 ± 10.23 89.97 ± 4.86 0.13 
Albumin 
excretion / 24 
hrs 
199.54 ± 72.21 19.97 ± 4.95 <0.00001 
 
 
 
‘P’ values < 0.05 statistically significant. ‘P’ values are rounded to 
two decimals 
SD means standard deviation 
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Table No.2 
 
Indicators of target organ damage 
 
 
Indicator 
Microalbuminuric 
Group 
Mean ± SD 
Normoalbuminuric 
group 
Mean ± SD 
‘P’ value 
LVMI 49.10 ± 7.36 42.54 ± 4.12 <0.00001 
IMT 1.01 ± 0.23 0.78 ± 0.07 <0.00001 
Uric acid 7.05 ± 1.33 6.1 ± 1.2 0.0052 
 
 
 
 
Table No.3 
 
Percentages of Left ventricular hypertrophy 
 
 
 
Microalbuminuric 
n = 26 
Normoalbuminuric 
n = 32 
LVH 11 1 
Percentage 42.30 % 3.12 % 
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Table No. 4 
 
 
Lipid profile in cases and controls 
 
 
Lipid fraction 
Microalbuminuric 
group 
Normoalbuminuric 
group 
P - value 
Total 
cholesterol 
207.65 ± 32.05 188.50 ± 38.93 2.055 
HDL 41.50 ± 4.01 45.16 ±  6.31 2.68 
Triglycerides 167.81 ± 53.14  195.94 ± 84.10 1.549 
LDL 132.59 ± 33.48 104.16 ± 32.97 3.237 
 
 
 
Table No. 5 
 
 
Levels of correlation with Microalbuminuria with TOD 
 
 
Factor Correlation coefficient 
LVMI 0.81 
Fundus 0.29 
IMT 0.37 
DBP 0.41 
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Data from 58 patients participated in this study is finally 
entertained for analysis of which 26 patients are cases (24 hr albumin 
excretion 30 – 300 mg) and 32 are designated as controls (24 hr 
albumin excretion <30 mg). The cases and controls are matched for 
age, sex, mean hypertension duration, systolic and diastolic blood 
pressures and body mass index as shown in Table 1. 
 
The cases and controls are age matched with a mean age of 
46.27 and 45.16 respectively. The male to female ratio in both cases 
and controls is 42.3 and 43.75 respectively. The body mass index 
(BMI) in cases and controls is 27.33 and 25.99 respectively. No 
statistical difference is found in age, mean hypertension duration and 
BMI between microalbuminuric and normoalbuminuric groups as 
evidenced by ‘P’ values 0.93, 0.54 and 0.16respectively (all P > 0.05). 
 
But this study found statistically significant difference in 
albumin excretion and LV mass index, Intima-media thickness, fundal 
changes with ‘P’ values <0.00001, <0.00001 and 0.0052 respectively 
(Table No.2) 
 
48 
 
Thus even after excluding some known risk factors for 
hypertension induced target organ damage and matching the rest 
between cases and controls, there existed statistically significant 
difference between these groups making evident that difference in 
prevalence of target organ damage in systemic hypertension is 
contributed by difference in albumin excretion hence this study 
concludes that MAL is an indicator of target organ damage in 
systemic hypertension. 
 
Further data from patients in both these group showed that there 
is close correlation between microalbuminuria and lipid abnormalities 
such as elevated total cholesterol (‘P’ < 0.05), elevated LDL 
(‘P’=0.0013) and reduced HDL (‘P’=0.0164). There is also close 
correlation between waist circumference and microalbuminuria 
indicating that central obesity is an important risk factor for target 
organ damage in systemic hypertension which is more common in 
Indian population which when added to the increased incidence of 
insulin resistance runs very high risk for adverse cardiovascular and 
central nervous system events. 
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Not only there is increased incidence of left ventricular 
hypertrophy in microalbuminuric group (Table No.3), but also there is 
strong linear correlation between LVMI and albumin excretion rate 
(correlation coefficient: 0.81 indicating very high correlation). Even 
though there is linear correlation between AER with fundal changes 
and IMT (correlation coefficients: 0.29 and 0.37 respectively), the 
relation is not as strong as with Left ventricular mass index (LVMI).  
  
The relationship of age to the amount of microalbuminuria is not 
well made out in our study. In past many researchers have shown that 
there is strong relationship between the amount of albumin excreted 
with increasing age both in diabetic and non-diabetic population. Our 
study did not elicit a good correlation. 
 
Increasing levels of albumin correlate with increasing levels of 
serum total cholesterol and decreasing levels of HDL, but the 
association was not statistically significant. In contrast to the earlier 
publications, that strongly came out with results of good correlation 
between atherogenic lipid profile and occurrence of target organ 
damage.
  
CHARTS 
 
Fig.1 
 
SEX RATIO (Male / Female) 
 
42.3
43.75
41
42
43
44
Cases Controls
Sex ratio 
 
 
 
Fig.2 
 
Hypertension duration 
 
0
5
10
15
20
N
u
m
be
r
1_3 3_6 7_9 9_12
Cases
Controls
 
 
  
Fig.3 
 
BMI 
 
0
4
8
12
16
<20 20-25 25-30 >30
Cases
Controls
 
 
 
Fig.4 
 
AGE DISTRIBUTION 
0
2
4
6
8
10
12
14
30-40 40-50 50-60
Cases
Controls
 
 
  
Fig.5 
 
MEAN LV MASS INDEX 
49.14
42.54
35
40
45
50
Cases Controls
LVMI
 
 
 
Fig.6 
 
 
MEAN INTIMA-MEDIA THICKNESS 
 
1.01
0.78
0
0.2
0.4
0.6
0.8
1
1.2
Cases Controls
Cases
Controls
 
 
 
  
Fig.7 
 
 
MEAN ALBUMIN EXCRETION RATE 
 
0
50
100
150
200
Cases Controls
Albumin excretion
rate
 
 
 
Fig.8 
 
 
MEAN URIC ACID LEVELS 
 
7.05
6.1
5
6
7
8
Cases Controls
Uric acid mg/dl
 
 
 
  
Fig.9 
 
CORRELATION BETWEEN LVMI AND AER 
IN MICROALBUMINURIC PATIENTS 
y = 0.0821x + 32.709
25
30
35
40
45
50
55
60
65
70
50 100 150 200 250 300
Alb
LV
MI
 
 
Fig.10 
 
CORRELATION BETWEEN IMT AND AER 
IN MICROALBUMINURIC PATIENTS 
 
y = 0.0012x + 0.7712
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
50 100 150 200 250 300
Alb
IM
T
 
 
  
Fig.11 
 
 
 
GRADES OF FUNDAL CHANGES - CONTROLS 
10
16
6
0
0
Grade 0
Grade 1
Grade 2
Grade 3
Grade 4
 
 
 
 
GRADES OF FUNDAL CHANGES – CASES 
3
8
11
4 0
Grade 0
Grade 1
Grade 2
Grade 3
Grade 4
 
 
  
Fig. 12 
 
Lipid profile in cases and controls 
0
50
100
150
200
250
TC HDL TGL LDL
cases
controls
 
 
 
Fig. 13 
 
Correlation between MAL and Damage indicators  
 
0 0.2 0.4 0.6 0.8 1
Fundus
IMT
DBP
LVMI
Correlation
coefficient
0.29 0.37 0.41 0.81
Fundus IMT DBP LVMI
50 
 
DISCUSSION 
 
 In this study on Indian population involving 58 patients we 
evaluated the occurrence of microalbuminuria as an indicator of 
subclinical target organ damage in systemic hypertension. This study 
shows target organ damage is more common in patients with 
microalbuminuria as well as without microalbuminuria. 
 
 Many studies have shown that microalbuminuria is a strong 
independent risk factor for CAD. This is evident from our study which 
also showed increased prevalence of target organ damage in 
microalbuminuric population even after matching of other coronary 
risk factors (BMI, age, duration of hypertension) and exclusion of 
some risk factors (smoking, DM) in both groups. 
 
 This study has attempted to show microalbuminuria as an 
indicator of subclinical target organ damage in patients with systemic 
hypertension without diabetes mellitus. Measurement of MAL in 
systemic hypertensive patients opens the possibility of various 
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therapeutic interventions to reduce MAL so as to reduce the 
prevalence of target organ damage in systemic hypertension. 
 
 This study also showed the linear correlation between the 
amount of albumin excretion and the severity of subclinical organ 
damage. It is also true in cases of microalbuminuria in diabetic 
individuals in whom the conversion from microalbuminuria to clinical 
albuminuria is an indicator of progression of diabetic nephropathy. In 
the correlation of AER with subclinical organ damage in various 
compartments, best correlation was with LVMI compared IMT or 
Fundal changes.  
 
 Our study has several limitations. First of all patients enrolled 
for the study are from hypertension clinic, the main reason for referral 
being poor control of hypertension which we haven’t taken into 
account potentially limiting the generalisability of the findings.  
 
 Secondly, though we measured traditional risk factors we failed 
to address about novel risk factors like small dense LDL, LP (a), and 
markers of endothelial dysfunction, regulators of coagulation and 
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fibrinolysis like PAI-1, which might have contributed to the 
difference. We have not measured albumin creatinine ratio or urine 
volume while calculating 24-hour albumin excretion rate, which might 
be confounding factors. 
 
Thirdly, we only measured total protein excretion in urine for 24 
hours semi-quantitatively, which may be an additional factor in the 
interpretation of the results of the study. 
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CONCLUSION 
 
The following are conclusions from the study 
 
1) Subclinical target organ damage is common in systemic 
hypertension, the probability of which is significantly increased 
in patients with microalbuminuria. 
 
2) In patients with microalbuminuria, the severity of target organ 
damage is directly related to the amount of albumin excretion in 
urine 
 
3) Microalbuminuria is an independent risk factor for target organ 
damage in systemic hypertension.  
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SCOPE OF FUTURE STUDIES 
 
  
This study conducted in Indian population has significant 
observations and potential therapeutic implications. Still few 
questions remain unanswered. Although microalbuminuria has been 
convincingly proved an independent cardiovascular risk factor, the 
exact pathophysiological mechanism of increased cardiovascular risk 
has to be elucidated by further studies. 
 
 The urinary excretion of transferrin protein is elevated in 
systemic hypertension. The relation of urinary transferrin excretion to 
the occurrence of target organ damage has to be confirmed by further 
studies. 
 
   
 
Microalbuminuria and target organ damage in systemic hypertension 
Proforma 
 
Name: 
Age: 
Sex: If female Menopause attained Y/N 
HTN OP No: 
DM  Y/N 
CKD Y/N 
CAD / MI/ DCM Y/N 
Diuretic use  Y/N 
Duration of HT  
Drugs used  
Avg. BP in past 3 months 
CVA  Y/N 
Angina / MI  Y/N 
Visual disturbance  Y/N 
Oliguria Y/N 
Nocturia  Y/N 
Pedal edema Y/N 
Abdominal pain Y/N 
Burning micturition Y/N 
Co-morbid conditions: 
Smoker: Type/ quantity/ duration 
Alcohol: Type/ quantity/ duration 
Family H/o DM/ SHT/ CVA/ CAD/ Renal disease 
 
Examination 
 Height  Weight Waist  Hip 
 Pulse  Peripheral pulses  Carotids  Equal/unequal 
BP (Upper limb) 
   
 
Fundus 
Arteriolar narrowing Y/N 
AV changes  Y/N 
Hemorrhages / cotton wool spots  Y/N 
Papilledema Y/N 
 CVS 
 Abdomen: Bruit  Y/N Aneurysm  Y/N 
 Neurological exam Focal neurological deficit Y/N 
 
INVESTIGATIONS 
 Blood glucose (Fasting):  Urea:  S. Creatinine: 
 Lipid profile: 
 Urine protein:  Sugar:  Deposits: 
 ECG (RE score)- 
  Largest R/S wave in limb lead > 20 mm  3 
  S wave in V1/V2 or R wave in V5/V6 > 30mm 3 
  Strain pattern      3 
  Left atrial enlargement    3 
  Left axis deviation     2 
  QRS duration > 0.09 sec    1 
  Intrinsicoid deflection > 0.05 sec   1 
 
Echocardiogram 
 Septal thickness 
 LV posterior wall thickness 
 LV internal diameter (diastole) 
 Fractional shortening 
 Ejection fraction 
 
Carotid intima-media thickness: R L 
 
Urine albumin 
 
Comments: 
   
 
 
 
S. 
No NAME AGE SEX DURn SBP DBP FUNDUS TC TGL HDL LDL LVMI Alb IMT 
Uric 
acid Wt Ht BMI WAIST HIP RATIO 
1 Amutha 45 F 4 112 80 0 190 110 40 128 44.49 87 0.70 7.6 70 163 26.35 115 119 0.97 
2 Anbu 43 M 8 148 96 2 207 158 38 137 57.67 270 1.35 8.2 67 162 25.53 123 108 1.14 
3 Anjaneyalu 36 M 4 134 94 0 185 112 45 118 39.33 156 1.50 5.2 65 158 26.04 98 90 1.09 
4 Balaji 50 M 9 130 90 3 207 158 48 127 52.67 230 1.10 8.2 67 162 25.53 89 92 0.97 
5 Devaki 54 F 9 148 88 2 197 175 41 121 56.33 268 1.00 7.2 87 156 35.75 85 100 0.85 
6 Duraisamy 43 M 6 120 80 1 232 300 37 135 47.67 178 0.95 6.8 78 171 26.67 99 96 1.03 
7 Egambaram 48 M 5 148 90 2 185 112 45 118 49.33 267 1.50 7.2 65 158 26.04 102 92 1.11 
8 Elizabeth 54 F 5 152 88 1 181 300 37 84 43.33 148 0.90 5.4 68 171 23.26 103 100 1.03 
9 Kannammal 47 F 4 130 92 1 169 165 47 89 42.00 57 0.65 6.9 78 158 31.24 106 119 0.89 
10 Kasthuri 55 F 1 178 98 0 220 146 41 150 42.33 187 0.85 4.7 64 164 23.80 98 92 1.07 
11 Kothandam 31 M 0 134 94 1 185 112 42 121 35.67 143 1.50 7.2 65 158 26.04 99 90 1.10 
12 Lakshmanamurthy 37 M 1 158 118 3 287 167 42 212 40.33 98 1.05 8.5 72 165 26.45 123 94 1.31 
13 Mariammal 52 F 8 146 90 1 190 145 37 124 48.33 256 1.10 7.8 60 163 22.58 99 93 1.06 
14 Mary 59 F 5 120 84 1 226 123 38 163 49.33 261 1.00 8.2 60 145 28.54 98 96 1.02 
15 Mumtaj 52 F 7 144 88 2 256 189 43 175 49.67 234 0.85 8.9 66 150 29.33 105 100 1.05 
16 Muniammal 52 F 1 114 90 2 220 146 42 149 58.67 213 0.95 4.7 74 164 27.51 94 87 1.08 
17 Natarajan 48 M 4 186 110 2 181 300 37 84 46.67 190 0.90 5.4 72 171 24.62 103 96 1.07 
18 Perumal 43 M 5 148 86 3 234 167 42 159 62.33 282 1.05 7.2 88 172 29.75 107 103 1.04 
19 Rajkumar 34 M 1 190 120 2 216 176 47 134 43.33 102 1.00 8.2 60 145 28.54 97 94 1.03 
20 Saradha 58 F 4 134 90 1 286 172 35 217 58.67 245 1.00 7.2 89 157 36.11 104 106 0.98 
21 Sarojiniammal 51 F 6 126 92 1 170 147 46 95 59.67 284 1.10 8.8 66 150 29.33 112 103 1.09 
22 Sivasubramaniam 45 M 7 152 94 2 190 156 43 116 54.67 278 0.95 5.9 60 163 22.58 107 98 1.09 
23 Sundarambal 48 M 1 162 80 2 189 156 42 116 50.33 223 1.00 8.2 60 145 28.54 97 96 1.01 
24 Syed allaudin 50 M 6 178 90 3 207 158 48 127 58.33 290 1.00 8.2 67 162 25.53 96 92 1.04 
25 Varadhan 31 M 0 134 94 2 220 148 42 148 43.00 154 0.75 4.7 64 164 23.80 96 90 1.07 
26 Venkatesan 37 M 1 172 106 2 169 165 34 102 42.34 87 0.65 6.8 78 158 31.24 95 94 1.01 
Microalbuminuric hypertensives 
   
 
S. 
No NAME AGE SEX DURn SBP DBP FUNDUS TC TGL HDL LDL LVMI Alb IMT 
Uric 
acid Wt Ht BMI WAIST HIP RATIO 
1 Anandhi 55 F 3 150 90 0 214 348 42 102 43.33 19 0.70 3.9 75 153 32.04 89 95 0.94 
2 Aravindh 38 M 4 150 90 0 155 84 53 85 45.58 26 0.80 6.8 51 173 17.04 73 90 0.81 
3 Inbaraj 43 M 7 148 86 0 228 322 38 126 43.15 23 0.80 5.0 73 158 29.24 97 108 0.90 
4 Jana 42 M 5 120 90 1 228 322 48 116 47.15 27 0.65 6.0 74 160 28.91 86 98 0.88 
5 Jeyadevan 33 M 0 140 95 1 203 220 38 121 41.00 17 0.75 5.8 64 172 21.63 92 97 0.95 
6 Kosumbu 60 F 7 144 80 1 160 186 45 78 42.78 10 0.75 7.5 67 156 27.53 99 123 0.80 
7 Kumar 37 M 2 148 92 1 160 186 45 78 42.33 12 0.80 7.5 62 156 25.48 100 105 0.95 
8 Latha 43 F 6 130 90 1 228 190 47 143 43.15 22 0.85 7.0 62 160 24.22 98 104 0.94 
9 Malarvizhi 60 F 1 144 80 1 169 147 42 98 43.33 16 0.75 5.3 60 155 24.97 95 97 0.98 
10 Malliga 58 F 5 148 90 1 156 175 42 79 51.02 13 0.90 4.5 82 168 29.05 104 106 0.98 
11 Marimuthu 35 M 2 148 92 1 140 110 56 62 45.00 16 0.80 6.0 65 164 24.17 87 93 0.94 
12 Mary jasmine 45 F 1 138 90 0 177 168 46 97 47.33 22 0.70 6.9 57 150 25.33 98 107 0.92 
13 Mohammal 54 F 3 150 90 0 140 110 56 62 46.67 17 0.65 5.1 65 156 26.71 100 95 1.05 
14 Muthu 42 M 6 140 90 1 203 220 38 121 37.33 29 0.75 8.9 59 156 24.24 103 97 1.06 
15 Natarajan 35 M 7 136 90 0 217 246 38 130 41.95 24 0.85 7.1 74 175 24.16 73 90 0.81 
16 Pachiammal 55 F 3 120 82 0 179 100 46 113 42.33 14 0.75 6.5 58 148 26.48 93 95 0.98 
17 Padmavathy 45 F 4 130 94 0 169 165 54 82 42.67 24 0.65 7.0 78 158 31.24 93 119 0.78 
18 Palaniyandi 46 M 9 140 90 2 167 268 39 74 43.67 15 0.80 5.3 60 155 24.97 98 95 1.03 
19 Penicilliah 44 M 3 136 102 2 321 294 48 214 39.30 27 0.90 5.3 60 155 24.97 103 98 1.05 
20 Rajesh khanna 31 M 2 138 90 0 155 84 53 85 40.67 24 0.80 6.8 64 173 21.38 73 90 0.81 
21 Ranganathan 41 M 10 140 90 2 217 246 38 130 39.33 17 0.70 7.1 74 175 24.16 96 103 0.93 
22 Ravindran 39 M 5 140 95 1 147 180 47 64 41.02 15 0.85 4.6 82 168 29.05 92 97 0.95 
23 Safira 44 F 3 127 92 2 140 110 56 62 41.57 25 0.90 5.6 65 170 22.49 95 98 0.97 
24 Santha 60 F 1 144 80 1 214 348 34 110 42.21 18 0.85 3.9 65 153 27.77 97 107 0.91 
25 Sasikumar 36 M 2 148 92 1 160 186 45 78 32.78 18 0.70 7.5 63 156 25.89 98 104 0.94 
26 Sathaya 41 M 3 125 98 2 179 100 46 113 35.71 24 0.75 6.5 54 148 24.65 103 98 1.05 
27 Shankar 38 M 4 140 95 1 214 348 44 100 33.00 21 0.85 3.9 75 153 32.04 92 97 0.95 
28 Sundarambal 56 F 6 146 84 1 217 246 38 130 43.67 16 0.85 7.0 74 165 27.18 104 106 0.98 
29 Sundari 52 F 6 148 90 1 155 84 53 85 47.67 19 0.75 6.8 62 173 20.72 94 106 0.89 
30 Surya 47 F 1 130 90 0 179 100 46 113 49.67 22 0.75 6.5 58 148 26.48 98 105 0.93 
31 Syed Ismail 48 M 1 140 90 2 203 220 48 111 44.00 20 0.80 6.0 58 165 21.30 113 105 1.08 
32 Vedagiri 42 M 2 128 90 1 238 157 36 171 41.02 27 0.90 5.9 102 168 36.14 123 100 1.23 
  
Normoalbuminuric hypertensives 
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